{"id":"W4387811279","doi":"10.1016/j.annonc.2023.09.2168","title":"1029P Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and anti-tumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":false,"ca_institutions":"University Health Network","funders":"Regeneron Pharmaceuticals; EMD Serono; Takeda Pharmaceuticals U.S.A.; Genentech; Amgen","keywords":"Medicine; Sting; Cytokine; Adverse effect; Pharmacology; Cytokine release syndrome; Internal medicine; Oncology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005544616,0.0004205015,0.000892283,0.0002612561,0.0002164157,0.000495057,0.0003950738,0.0004867365,0.002547055],"category_scores_gemma":[0.0004868154,0.0002604175,0.0004734875,0.0003070028,0.0003249113,0.0004367928,0.0002022659,0.001723427,0.0006895994],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003897296,"about_ca_system_score_gemma":0.0004227291,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005378023,"about_ca_topic_score_gemma":0.00174108,"domain_scores_codex":[0.9998057,0.00007585959,0.00001058789,0.00002905308,0.00002230929,0.0000564944],"domain_scores_gemma":[0.999803,0.00004332031,0.00003132326,0.00001785648,0.000009774944,0.0000947389],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3374572,0.0252649,0.009871675,0.0004924071,0.001092505,0.0004926415,0.000262979,0.003583816,0.1576576,0.0005012773,0.004182559,0.4591405],"study_design_scores_gemma":[0.1961525,0.6788665,0.06283061,0.0001023491,0.0009999463,0.001653663,0.0001789163,0.007055294,0.04107009,0.000470729,0.01055559,0.00006377754],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947801,0.002127258,0.0004060109,0.0002784889,0.00007968301,0.0002017495,0.0001939569,0.00008199803,0.001850908],"genre_scores_gemma":[0.9963824,0.0008509116,0.0008069464,0.0001852918,0.0000487584,0.0001145353,0.0003377124,0.00001021014,0.001263212],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002547055,"threshold_uncertainty_score":0.008520722,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04695138383112311,"score_gpt":0.3784341755660882,"score_spread":0.331482791734965,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}